1. Volume 153, Issue 4, Pages 782-784 (April 2018)
COUNTERPOINT: Should an Attempt Be Made to Withdraw Inhaled Corticosteroids in All Patients With Stable GOLD 3 (30% ≤ FEV1 < 50% Predicted) COPD? No 
Ian D. Pavord, FMedSci 
CHEST 
Volume 153, Issue 4, Pages (April 2018)
DOI: /j.chest
Copyright © 2018 American College of Chest Physicians Terms and Conditions

2. Figure 1
Proposed management of COPD incorporating two major treatable traits: symptoms due to airflow limitation and risk assessed using the blood eosinophil count. Risk refers to future risk of exacerbation and decline in FEV1. Treatments with a trait-specific effect are included. Rescue short-acting bronchodilators (SABA or SAMA) could be used in all situations and patient categories, as required. ICS = inhaled corticosteroid; CS = corticosteroid; LABA = long-acting β2-agonist; LAMA = long-acting muscarinic antagonist; PRN = as needed; SABA = short-acting β2-agonist; SAMA = short-acting muscarinic antagonist.
CHEST  , DOI: ( /j.chest )
Copyright © 2018 American College of Chest Physicians Terms and Conditions